Compare Ginkgo Bioworks Holdings Inc (DNA) vs Atlassian Corporation PLC (TEAM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Ginkgo Bioworks Holdings Inc vs Atlassian Corporation PLC — how do they compare? Ginkgo Bioworks Holdings Inc trades at $9.1 (market cap $590.53M), while Atlassian Corporation PLC trades at $92.33 (market cap $22.62B). The key difference: Atlassian Corporation PLC is far larger — about 38.3× Ginkgo Bioworks Holdings Inc's market cap. Which is the better fit depends on your goals.
| DNA | TEAM | |
|---|---|---|
Market Cap | $590.53M | $22.62B |
Sector | Health | Technology |
52-Week High | $16.14 | $203.00 |
52-Week Low | $5.48 | $57.15 |
Enterprise Value | $627.78M | $22.73B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DNA trades at $9.05, down 0.44% on the day, reflecting ongoing investor caution. The technical outlook is bearish, while fundamentals show significant losses with a net income margin of -201.05% and negative cash flows. Recent earnings have been mixed, missing estimates in two of the last three quarters. Analyst sentiment is divided, with a slight lean toward buy ratings amid high volatility and operational challenges.
The outlook remains challenging due to persistent losses and cash burn, though analyst coverage suggests potential long-term value. Key risks include execution missteps and intense competition in biotechnology. Investment appeal hinges on future profitability improvements and successful business model execution.
Atlassian (TEAM) trades at $96.11, up 8.16% today, with strong technical momentum and bullish analyst sentiment. The stock shows accelerating revenue growth (32% YoY in Q3 FY26 per Zacks Investment Research, 2026-06-24) and improving margins, though it remains unprofitable. Recent earnings beats and cloud business expansion support positive outlook, while high valuation multiples and competitive pressures present risks.
Outlook remains positive driven by enterprise adoption and AI integration, but investors face risks from persistent net losses and elevated valuation. Wall Street consensus price target of $115.69 suggests 20% upside, though execution on profitability is critical for sustained gains.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Ginkgo Bioworks Holdings Inc
Ginkgo Bioworks is a leading horizontal platform for cell programming. It uses advanced automation and software to design custom organisms for customers across diverse industries, including food, agriculture, and pharma.
Read more on DNA →About Atlassian Corporation PLC
Atlassian produces software that helps teams work together more efficiently and effectively. The company provides project planning and management software, collaboration tools, and IT help desk solutions. The company operates in four segments: subscriptions (term licenses and cloud agreements), maintenance (annual maintenance contracts that provide support and periodic updates and are generally attached to perpetual license sales), perpetual license (upfront sale for indefinite usage of the software), and other (training, strategic consulting, and revenue from the Atlassian Marketplace app store). Atlassian was founded in 2002 and is headquartered in Sydney.
Read more on TEAM →
